Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 11 April 2017, 11:42 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch "Chocola BB Gold Rich" Highest Combination of Active Ingredients in Chocola BB Series
Easy to Drink Bergamot Flavor

TOKYO, Apr 11, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that, approaching the 65th anniversary of its Chocola BB brand, it will launch Chocola BB Gold Rich (designated quasi-drug), a supplement drink recommended to relieve fatigue, on Monday, April 17. Chocola BB Gold Rich is a luxurious combination of 16 active ingredients, the highest number in the Chocola BB series. It contains active ingredients including B-complex vitamins and taurine 1500mg to help a fatigued body produce energy, and six natural herbs carefully selected by female developers to please female consumers, including angelica acutiloba, ginseng, and royal jelly. The bergamot orange flavor, which is also used in Earl Grey tea and other products, is easy to drink, and the gold and pink packaging is elegantly designed to give off a sense of luxury. This boxed supplement drink from the Chocola BB brand has been designed to be approachable for female consumers.

Chocola BB Gold Rich

In recent years, along with the increasing social advancement of women, the market catering to female supplement drink consumers is also growing. Additionally, consumers drink different products depending on their level of fatigue. This product is designed to respond to the needs of women who want a high performance drink. Chocola BB Gold Rich is a speedy fatigue reliever perfect for busy women in the office or at home.

The Chocola BB supplement drink series includes Chocola BB Light 2 for day-to-day fatigue, Chocola BB Royal 2 for extreme fatigue, and Chocola BB Hyper for weak constitutions, all of which are marketed as designated quasi-drug products designed to help relieve fatigue.

Through the Chocola BB brand, Eisai will continue to respond to the diverse needs of female consumers and support an ever-growing number of people to achieve health and beauty in their everyday lives.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120



Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Apr 18, 2024 09:53 HKT/SGT
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Apr 17, 2024 15:17 HKT/SGT
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
Apr 3, 2024 15:24 HKT/SGT
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Apr 1, 2024 08:39 HKT/SGT
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Mar 29, 2024 14:51 HKT/SGT
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
Mar 29, 2024 14:19 HKT/SGT
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
Mar 29, 2024 13:32 HKT/SGT
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
Mar 21, 2024 16:36 HKT/SGT
Lifenet and Eisai Co-Develop Dementia Insurance "be"
Mar 21, 2024 15:10 HKT/SGT
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
Mar 6, 2024 16:47 HKT/SGT
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: